Solid Tumor Testing Market Size

The global solid tumor testing market size was valued at around USD 20.5 billion in 2023 and is estimated to grow at 7.6% CAGR from 2024 to 2032. Rising cancer incidences and increasing awareness and demand are driving the growth of the market.

The growing prevalence of cancer significantly impacts the demand for accurate and timely diagnostic solutions, leading to the expansion of the market. As more individuals are diagnosed with various types of solid tumors, healthcare providers are compelled to enhance their testing capabilities to ensure effective treatment and management.

Several factors contribute to the rising cancer rates, including unhealthy lifestyle choices such as poor diet, physical inactivity, tobacco use, and excessive alcohol consumption, all of which have been linked to an increased risk of cancer. For example, according to the Centers for Disease Control and Prevention (CDC), nearly 1.78 million new cases of invasive cancer occurred in the U.S. in 2021, with an incidence rate of 439 per 100,000 people.

Additionally, growing awareness and demand for solid tumor testing are significantly driving market growth by encouraging early detection and personalized treatment options. As patients and healthcare providers become more informed about the benefits of genomic testing and biomarker profiling, there is an increasing push for advanced diagnostic solutions that can lead to better treatment outcomes. This heightened awareness is also fostering investments in research and development, further propelling innovations in testing technologies.

Solid tumor testing refers to molecular diagnostic testing that analyzes a solid mass of cancerous tissue to identify genetic mutations, biomarkers, or other molecular characteristics. This testing helps guide treatment decisions, such as selecting targeted therapies or immunotherapies, and assessing the likelihood of cancer recurrence.

Solid Tumor Testing Market Trends

• The market is experiencing a surge in technological advancements that are revolutionizing the detection, diagnosis, and management of solid tumors.
  
• Next-Generation Sequencing (NGS) stands at the forefront of these innovations, enabling high-throughput analyses of multiple genes simultaneously, thereby enhancing efficiency and accuracy in cancer diagnostics. NGS also allows for the analysis of DNA methylation patterns and RNA sequencing, providing deeper insights into tumor biology and supporting personalized treatment approaches.
  
• Advancements in imaging technologies, such as molecular imaging, enable the visualization of biological processes at the molecular level, aiding in early tumor detection and treatment efficacy assessment.
  
• The integration of artificial intelligence (AI) algorithms further enhances image analysis, improving accuracy in detecting and classifying tumors from imaging studies.
  
• Additionally, the identification and validation of new cancer biomarkers are crucial for improving diagnostic precision. For example, recent advancements include the development of multiplex biomarker panels, which allow for the simultaneous assessment of multiple biomarkers from a single sample, enhancing diagnostic capabilities and treatment stratification.
  
• These technological advancements not only improve the accuracy and speed of solid tumor diagnostics but also support personalized treatment strategies, ultimately leading to better patient outcomes in cancer care.
  

Solid Tumor Testing Market Analysis

Based on type, the market is segmented into genetic testing and conventional testing. The genetic testing segment dominated the market in 2023 and accounted for USD 13.6 billion.

• Genetic testing provides more precise and detailed insights into the molecular and genetic profiles of tumors, enabling targeted therapies that are customized to individual patients. This leads to improved treatment outcomes by matching therapies to specific genetic mutations.
  
• Additionally, the rise of next-generation sequencing (NGS) technologies has significantly reduced the cost and time required for genetic testing, making it more accessible and widely adopted, contributing to the segment's growth.
  

Based on application, the solid tumor testing market is segmented into breast cancer, lung cancer, prostate cancer, colorectal cancer, melanoma, and other applications. The breast cancer segment dominated the market in 2023 with a market share of 25.9%.

• Breast cancer is one of the most commonly diagnosed cancers globally, particularly among women. Its high incidence drives a strong demand for breast cancer diagnostics and early detection, making it a key application in tumor testing.
  
• Furthermore, awareness programs and regular screening initiatives, such as mammograms and genetic tests for BRCA1/BRCA2 mutations, have become standard practice in many countries, leading to a higher volume of diagnostic tests.
  

Based on end-use, the solid tumor testing market is segmented into hospitals, diagnostics laboratories, cancer research institutes, and other end-users. The hospitals segment is anticipated to reach USD 13.8 billion by 2032.

• Hospitals typically handle a larger number of patients compared to other healthcare settings, leading to a higher demand for diagnostic tests, including solid tumor testing. Hospitals are often the first point of contact for cancer diagnosis and treatment.
  
• Additionally, hospitals are equipped with advanced diagnostic technologies, such as imaging and genetic testing tools, making them the primary location for comprehensive cancer testing and treatment. They also have multidisciplinary teams that coordinate the use of these tests in patient care.
  

North America solid tumor testing market accounted for USD 7.7 billion market revenue in 2023 and is anticipated to grow at CAGR of 7.3% between 2024 to 2032.

• North America's well-established healthcare system and widespread access to cutting-edge diagnostic technologies are fueling demand for solid tumor testing.
  
• Additionally, the trend toward precision oncology, which tailors’ treatment to individual tumor genetic profiles, is a significant driver. Advancements in genomic technologies, such as next-generation sequencing (NGS), have transformed solid tumor testing by enabling detailed analysis of cancer mutations and molecular biomarkers. Thus, driving the North America market.
  

The U.S. held a dominant position in the solid tumor testing market, with a revenue of USD 7.1 billion in 2023.

• The U.S. has a high and growing number of cancer cases, leading to increased demand for early detection and diagnostic tests, including solid tumor testing.
  
• Additionally, supportive policies, such as Medicare and Medicaid reimbursement for genetic and molecular tests, encourage the adoption of advanced tumor testing solutions.
  

UK solid tumor testing market is anticipated to witness substantial growth during 2024 to 2032 timeframe.

• The UK has well-established cancer screening programs, such as the NHS Breast Screening Program, which increase disease awareness among the population and boost the volume of testing for solid tumors.
  
• Moreover, the UK is a hub for cancer research, leading to innovations in diagnostic testing and creating robust demand for tumor testing in both research and clinical settings.
  

Japan holds a dominant position in the Asia Pacific solid tumor testing market.

• Japan has a high incidence of cancer, particularly lung, breast, and colorectal cancers. The aging population and lifestyle factors contribute to this rise, increasing the demand for effective diagnostic solutions.
  
• The Japanese government is promoting cancer research and treatment through various initiatives, including funding and regulatory support for innovative diagnostic technologies. This encourages the development and adoption of solid tumor testing methods.
  

Solid Tumor Testing Market Share

The market is fragmented, comprising a mix of large multinational corporations and numerous small to mid-sized companies vying for market share. Key strategies driving growth in this sector include the development and introduction of innovative testing methods that offer enhanced accuracy, efficiency, and cost-effectiveness. This emphasis on innovation is crucial for addressing the evolving needs of clinical diagnostics and research, as well as for improving patient outcomes. As companies strive to remain competitive, their advancements in solid tumor testing play a pivotal role in capturing market share and meeting the increasing demand for sophisticated testing tools.

Solid Tumor Testing Market Companies

Some of the eminent market participants operating in the solid tumor testing industry include:

• Abbott
• Agilent Technologies, Inc.
• Caris Life Sciences
• F. Hoffmann-La Roche Ltd
• Foundation Medicine, Inc.
• Guardant Health
• Hologic, Inc.
• Illumina, Inc.
• MedGenome
• Myriad Genetics, Inc.
• NeoGenomics Laboratories
• QIAGEN
• Quest Diagnostics Incorporated
• SOPHiA GENETICS
• Thermo Fisher Scientific, Inc.
  

Solid Tumor Testing Industry News:

• In August 2024, Illumina, Inc., announced the Food and Drug Administration (FDA) approval for its TruSight Oncology (TSO) Comprehensive test, an in-vitro diagnostic testing. This approval is expected to increase the company’s competitiveness in the market and enhance its reputation.
  
• In March 2023, NeoGenomics, Inc. announced the expansion of its next-generation sequencing (NGS) portfolio with the commercial availability of multiple innovative tests, including the Neo Comprehensive - solid tumor test, which provides a comprehensive genomic profile (CGP) for solid tumor cancers, and the Neo Comprehensive - Myeloid disorders test for myeloid neoplasms. This expansion enhanced the company’s product offerings, allowing them to provide a broader spectrum of advanced genomic testing solutions.
  

Solid tumor testing market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Type   

• Genetic testing
  • Next-generation sequencing (NGS)
  • Polymerase chain reaction (PCR)
  • Fluorescence in situ hybridization (FISH)
  • In situ hybridization (ISH)
• Conventional testing

Market, By Application

• Breast cancer
• Lung cancer
• Prostate cancer
• Colorectal cancer
• Melanoma
• Other applications

Market, By End Use

• Hospitals
• Diagnostic laboratories
• Cancer research institutes
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa